U.S. Food and Drug Administration

The U.S. Food and Drug Administration (FDA) is a regulatory commission that oversees food, drugs, medical devices, vaccines, tobacco products and more for the United States. To date, the FDA has not approved any drugs for the use of Myalgic Encephalomyelitis & Chronic Fatigue Syndrome.

FDA activities on drug development for Myalgic Encephalomyelitis & Chronic Fatigue Syndrome

 * 23 Apr, 2014 FDA Webinar: Guidance for Industry Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis: Developing Drug Products for Treatment by Janet Maynard, MD, MP
 * Webinar
 * Slides
 * Follow-up to the April 23, 2014 Webinar - Written Questions and Answers


 * 11 Mar 2014, Federal Register Notice of Draft Guidance for Industry on Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drug Products for Treatment; Availability
 * 10 Mar 2014, Guidance for Industry Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis: Developing Drug Products for Treatment (12 pages)
 * 16 Oct 2013, Chronic Fatigue Syndrome and Myalgic Encephalomyelitis (CFS and ME) Stakeholder Teleconference Transcript of Teleconference
 * 26 Apr 2013, CFS and ME Meeting Summary
 * 25-26 Apr 2013, FDA Workshop on Drug Development for Chronic Fatigue Syndrome (CFS) and Myalgic Encephalomyelitis (ME)
 * 25 Apr 2013, "The Voice of the Patient" - Report on FDA public meeting for ME/CFS
 * 18 Apr 2013, FDA 101 Webinar by David Banks. PhD
 * 15 Nov 2012, Myalgic Encephalomyelitis and Chronic Fatigue Syndrome Webinar: Working Together for Change
 * 13 Sept 2012, Teleconference between FDA and Patients/Patient Advocates

FDA response to Ampligen approval

 * 2013, Response Letter Regarding Approval of Ampligen for ME/CFS
 * 2013, Drug Development for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS): Questions and Answers (Ampligen)